Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2415018
Max Phase: Preclinical
Molecular Formula: C118H178N28O16
Molecular Weight: 2244.90
Molecule Type: Unknown
Associated Items:
ID: ALA2415018
Max Phase: Preclinical
Molecular Formula: C118H178N28O16
Molecular Weight: 2244.90
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)C(O)CCC(C)C(O)CCC(C)C(CCC(O)C(C)CCC(O)C(C)CCC(OCCCCc1cn(CCCCCC(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(N)=O)nn1)C(C)C)OCCCCc1cn(CCCCCC(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(N)=O)nn1
Standard InChI: InChI=1S/C118H178N28O16/c1-75(2)101(147)49-45-77(5)103(149)51-47-80(8)106(162-60-28-24-36-86-72-146(144-142-86)58-26-12-18-44-108(152)134-100(66-88-70-126-74-132-88)116(160)140-98(62-82-33-15-10-16-34-82)114(158)136-94(42-30-56-128-118(123)124)112(156)138-96(110(120)154)64-84-68-130-92-40-22-20-38-90(84)92)54-52-104(150)78(6)46-50-102(148)79(7)48-53-105(76(3)4)161-59-27-23-35-85-71-145(143-141-85)57-25-11-17-43-107(151)133-99(65-87-69-125-73-131-87)115(159)139-97(61-81-31-13-9-14-32-81)113(157)135-93(41-29-55-127-117(121)122)111(155)137-95(109(119)153)63-83-67-129-91-39-21-19-37-89(83)91/h9-10,13-16,19-22,31-34,37-40,67-80,93-106,129-130,147-150H,11-12,17-18,23-30,35-36,41-66H2,1-8H3,(H2,119,153)(H2,120,154)(H,125,131)(H,126,132)(H,133,151)(H,134,152)(H,135,157)(H,136,158)(H,137,155)(H,138,156)(H,139,159)(H,140,160)(H4,121,122,127)(H4,123,124,128)/t77?,78?,79?,80?,93-,94-,95-,96-,97+,98+,99-,100-,101?,102?,103?,104?,105?,106?/m0/s1
Standard InChI Key: SDCXHZWWIVATCT-DXPBVPIUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2244.90 | Molecular Weight (Monoisotopic): 2243.3976 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Alleti R, Vagner J, Dehigaspitiya DC, Moberg VE, Elshan NG, Tafreshi NK, Brabez N, Weber CS, Lynch RM, Hruby VJ, Gillies RJ, Morse DL, Mash EA.. (2013) Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptors., 21 (17): [PMID:23890524] [10.1016/j.bmc.2013.06.052] |
Source(1):